FindTrial
Sign In

Selenium supplementation for the prevention of hepatocellular carcinomas in HBsAg positive patients (pilot study)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN38534743
Enrollment
Unknown
Registered
2003-09-23
Start date
2000-01-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevention of primary liver cancer with selenium supplementation - targeted to high risk population Cancer Liver cancer

Interventions

Eligible patients who consent to participate will be randomly allocated to the selenium group (oral selenium supplementation: 200mg selenium per day, in the form of selenized yeast tablet) or control

Sponsors

The University of Birmingham (UK)
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Participants will include: 1. Men aged 45 to 64 with positive HBsAg (hepatitis B surface antigen) test 2. Negative AFP (alphafetoprotein) test 3. Normal ALT (alanine aminotransferase) values

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026